Last year was far from vintage for the biotech sector in terms of stock performance: the S&P Biotechnology Select Industry Index rose by only 3% in 2024, and lagged far behind the 25% achieved by the S&P 500 and big tech firms, which hit record highs.
Mid-Cap Biopharma’s Biggest Winners And Losers Of 2024
Summit Therapeutics hit the stock market heights in 2024, along with a handful of biotech with novel therapies and platforms, while Moderna was dragged down by shrinking COVID-19 vaccine sales.
